Blauvelt, A. ., Rich, P., Sofen, H., Lambert, J., Merola, J., Lebwohl, M., Hippeli, L., Kisa, R., Banerjee, S. and Kimball, A. (2022) “Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and PSO-2 trials”, SKIN The Journal of Cutaneous Medicine, 6(4), p. s41. doi: 10.25251/skin.6.supp.41.